Atipamezole
- Generic Name
- Atipamezole
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N2
- CAS Number
- 104054-27-5
- Unique Ingredient Identifier
- 03N9U5JAF6
- Background
Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. It has also been undergone research as a potential anti-Parkinsonian drug for humans.
- Indication
For the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.
Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed
Phase 1
Withdrawn
- Conditions
- Emergence From Anesthesia
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT04942340
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 10
- Registration Number
- NCT01435213
- Locations
- 🇫🇮
University of Turku, Clinical Research Services Turku CRST, Turku, Finland
🇫🇮University of Turku, Turku PET Centre, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath